Food and Drug Administration

Multiple Myeloma Treatment: European Union Approves Novartis’ Farydak For Patients With Advanced Multiple Myeloma

Multiple myeloma is one of the most uncommon types of cancer, but no less deadly because of it, as patients of the plasma cells disease will survive, on a median, for 3 or 4 years, with further multiple myeloma treatments possibly extending survival up to 5 to 7 years.
More News